UFP Technologies (UFPT) Peer Comparison

$300.05

$0.10 (0.03%)

As on 28-Aug-2026 16:00EDT

Market cap

$2,324 Mln

Revenue (TTM)

$632 Mln

P/E Ratio

32.4

P/B Ratio

5

Div. Yield

0 %

Edit

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	2,324	12,753	10,906	9,948	9,762
Revenue ($ Mln)	632	1,505	613	785	2,589
Net Profit ($ Mln)	72.30	160.59	-188.05	41.54	222.40
Net Margin (%)	11.45	10.67	-30.68	5.29	8.59
RoE (%)	16.31	10.86	-28.10	1.97	3.04
Price to Earnings	32.44	79.35	--	251.81	44.47
Price-To-Book	5.03	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	631.64	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	451.64	483.98	127.96	384.30	1,245.50
Gross Profit	170.41	942.44	393.22	347.62	1,343.60
Operating Expenses	83.68	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	96.32	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	88.64	203.83	-192.83	52.15	350.40
Provision for Tax	16.35	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	72.30	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	462.43	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	141.18	210.18	135.71	705.49	2,116.80
Current Liabilities	78.30	233.78	102.33	132.66	961.30
Total Liabilities	665.74	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	447.02	630.60	404.74	1,749.63	7,231.50
Current Assets	234.89	1,344.12	515.78	1,200.55	3,020.50
Total Assets	665.74	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	136.34	212.71	102.84	690.94	1,203.70
Net Current Assets	156.59	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	91.91	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-27.60	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-58.16	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	12.12	11.76	-22.53	1.79	8.98
ROE (%)	16.31	10.86	-28.10	1.97	3.04
ROA (%)	9.88	7.95	-18.00	1.36	2.02
EBIT Margin (%)	15.26	13.63	-30.58	9.87	-5.99
Net Margin (%)	11.45	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	7.32	17.55	41.55	16.49	1.37
EBIT Growth (%)	1.96	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	7.74	8.72	-102.66	400.42	-30.32
EPS Growth (%)	7.52	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	19.60	17.33	-12.65	2.16	2.19

Valuation Ratios

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	25.36	68.93	-34.59	189.42	--
Price / Book Value	4.09	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	16.13	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.23	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.04	0.01	0.00	0.01	0.06
Current Ratio	3.00	5.75	5.04	9.05	3.14
Quick Ratio	1.72	3.86	4.46	7.64	2.33
Interest Coverage	12.41	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	UFP Technologies (UFPT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	18.58	12.65	22.67	20.09	17.06
Asset Turnover	0.86	0.74	0.59	0.26	0.24
Receivable days	53.89	46.54	60.95	72.41	65.39
Inventory Days	73.66	331.92	193.84	146.53	221.09
Payable days	20.51	26.16	60.19	29.05	37.02
Cash Conversion Cycle	107.04	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly